{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:22:30Z","timestamp":1760314950066,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,1,15]]},"abstract":"<jats:p>Imatinib should continue to be the front\u2010line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second\u2010generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.<\/jats:p>","DOI":"10.1002\/cncr.25600","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T10:05:58Z","timestamp":1288087558000},"page":"234-237","source":"Crossref","is-referenced-by-count":5,"title":["Second\u2010generation tyrosine kinase inhibitors in chronic myelogenous leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,26]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1924.02650450001001"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04912.x"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700933"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.3.689.689"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_3_8_2","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood."},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403006"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3074"},{"key":"e_1_2_3_11_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V92.5.1541","volume":"92","author":"[No authors listed] Long\u2010term follow\u2010up of the Italian trial of interferon\u2010alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1998","journal-title":"Blood"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00061-7"},{"key":"e_1_2_3_13_2","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood.V94.11.3668","article-title":"Interferon\u2010alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure","volume":"94","author":"Hehlmann R","year":"1999","journal-title":"Blood"},{"key":"e_1_2_3_14_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.1993.11.6.1055","article-title":"Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia","volume":"11","author":"Giralt SA","year":"1993","journal-title":"J Clin Oncol."},{"key":"e_1_2_3_15_2","first-page":"231","article-title":"Prior treatment with alpha\u2010interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia","volume":"83","author":"Zuffa E","year":"1998","journal-title":"Haematologica."},{"key":"e_1_2_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_3_18_2","first-page":"100","article-title":"Inhibition of the Abl protein\u2010tyrosine kinase in vitro and in vivo by a 2\u2010phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_3_22_2","first-page":"327","article-title":"Current event\u2010free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"116","author":"Al\u2010Kali A","year":"2010","journal-title":"Cancer"},{"key":"e_1_2_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_3_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2011"},{"key":"e_1_2_3_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24418"},{"key":"e_1_2_3_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197715"},{"key":"e_1_2_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24325"},{"key":"e_1_2_3_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021154"},{"key":"e_1_2_3_35_2","first-page":"320","article-title":"Ein Symptomatisch ausgezichneter Fall von Leucaemie","volume":"2","author":"Valentiner W.","year":"1865","journal-title":"Berl Klin Wochenschr."},{"key":"e_1_2_3_36_2","first-page":"403","article-title":"Zwei Falle von Leucaemie","volume":"2","author":"Lissauer H.","year":"1865","journal-title":"Berl Klin Wochenschr."},{"key":"e_1_2_3_37_2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","journal-title":"J Natl Cancer Inst."},{"key":"e_1_2_3_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2947"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25600","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:57:26Z","timestamp":1760259446000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25600"}},"subtitle":["Before or after imatinib?"],"short-title":[],"issued":{"date-parts":[[2010,10,26]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1,15]]}},"alternative-id":["10.1002\/cncr.25600"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25600","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,10,26]]}}}